Cytokinetics Inc
CYTK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001061983
In the last 90 days, Cytokinetics Inc insiders filed 0 open-market purchases and 16 sales; 485 institutions reported holding it in 13F filings for Q2 2026, worth $13.7B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $7.82B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $12.2M in total
- 16
- 13F holdersQ2 2026, +46 vs. previous quarter
- 485
- 13F valueReported value at the end of Q2 2026
- $13.7B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $88.0M
- +376.6% year over year
- Net income, FY2025
- -$785.0M
- No comparable prior period
- Free cash flow, FY2025
- -$534.8M
- No comparable prior period
- Revenue, Q3 FY2026
- $47.6M
- +2,356.5% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $785.0M (891.6% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 17.9M
- Shares sold short
- Change
- −698.5K
- −3.8% vs. previous
- Days to cover
- 14.15
- At average daily volume
Superinvestors holding CYTK, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CYTK at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Cytokinetics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 (view filing)4:41 PM ET | Nov 9 | 3 days | Parshall B LynneDirector | SSale | −5.00K | $54.73 | −$273.6K | −46.4%5.78K after | 2 lots10b5-1 |
| Nov 3, 2026 (view filing)4:38 PM ET | Nov 3 | Same day | Malik Fady IbrahamEVP Research & Development | SSale | −3.50K | $62.93 | −$220.3K | −2.2%153.9K after | 10b5-1 |
| Nov 2, 2026 (view filing)6:18 PM ET | Nov 2 | Same day | Blum Robert IPresident & CEO | SSale | −7.50K | $62.81 | −$471.1K | −2.6%278.5K after | 10b5-1 |
| Oct 20, 2026 (view filing)4:21 PM ET | Oct 20 | Same day | Malik Fady IbrahamEVP Research & Development | SSale | −3.50K | $64.01 | −$224.0K | −2.2%153.9K after | 10b5-1 |
| Oct 13, 2026 (view filing)4:00 PM ET | Oct 12 | 1 day | Blum Robert IPresident & CEO | SSale | −7.50K | $62.88 | −$471.6K | −2.6%278.5K after | 10b5-1 |
| Oct 6, 2026 (view filing)4:25 PM ET | Oct 6 | Same day | Malik Fady IbrahamEVP Research & Development | SSale | −3.50K | $61.38 | −$214.8K | −2.2%153.9K after | 10b5-1 |
| Sep 28, 2026 (view filing)4:54 PM ET | Sep 28 | Same day | Blum Robert IPresident & CEO | SSale | −7.50K | $65.46 | −$490.9K | −2.6%278.5K after | 10b5-1 |
| Sep 22, 2026 (view filing)6:14 PM ET | Sep 22 | Same day | Malik Fady IbrahamEVP Research & Development | SSale | −3.50K | $68.29 | −$239.0K | −2.2%153.9K after | 10b5-1 |
| Sep 15, 2026 (view filing)5:23 PM ET | Sep 15 | Same day | Landry Robert EDirector | SSale | −1.00K | $72.13 | −$72.1K | −10.9%8.18K after | 10b5-1 |
| Sep 15, 2026 (view filing)5:20 PM ET | Sep 14 | 1 day | Blum Robert IPresident & CEO | SSale | −7.50K | $73.44 | −$550.8K | −1.9%377.8K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 485 holdersThe largest institutional positions in Cytokinetics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,094,362 | $1.71B | 0.03% | +3,546,351+21.4% | Added |
| T. Rowe Price Investment Management, Inc. | 18,718,498 | $1.59B | 1.05% | +1,194,658+6.8% | Added |
| Wellington Management Group LLP | 6,931,770 | $590.5M | 0.10% | −1,077,719−13.5% | Reduced |
| Vanguard Portfolio Management LLC | 6,711,799 | $571.8M | 0.03% | +868,017+14.9% | Added |
| State Street Corp | 6,494,233 | $553.2M | 0.02% | +749,040+13.0% | Added |
| Vanguard Capital Management LLC | 6,117,515 | $521.2M | 0.01% | +628,881+11.5% | Added |
| FMR LLC | 5,031,782 | $428.7M | 0.02% | −5,691,358−53.1% | Reduced |
| Avoro Capital Advisors LLC | 4,999,999 | $425.9M | 3.82% | +1,666,666+50.0% | Added |
| Bank of America Corp | 4,635,709 | $394.9M | 0.03% | +1,510,273+48.3% | Added |
| Geode Capital Management, LLC | 3,712,501 | $316.3M | 0.02% | +497,086+15.5% | Added |
Holders of 5% or more of CYTK
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Cytokinetics Inc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/A | 14.50%17.7M shares | −1.50 ppfrom 16.00% | Nov 14, 20245 filings | Feb 17, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.21%6.42M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
| State Street Corp | 13G | 5.10%7.14M shares | +0.40 ppfrom 4.70% | Feb 8, 20216 filings | Nov 10, 2026 | SEC |
| Wellington Management Group LLP | 13G/A | 5.10%7.12M shares | – | Feb 6, 20233 filings | Aug 13, 2026 | SEC |
Politician trades
All politician trades in CYTK2 members of Congress reported 5 trades in Cytokinetics Inc since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Oct 12, 2026 |  Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Jul 2, 2026 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Nov 18, 2025 | Gilbert Ray Cisneros, Jr. House · CA | Buy | $1K-$15K |
| Aug 13, 2025 |  Lisa C. McClain House · MI | Sell | $1K-$15K |
| Aug 13, 2025 | Lisa C. McClain House · MI | Buy | $1K-$15K |
House · CA · Oct 12, 2026
Buy$1K-$15K
House · CA · Jul 2, 2026
Buy$1K-$15K
House · CA · Nov 18, 2025
Buy$1K-$15K
House · MI · Aug 13, 2025
Sell$1K-$15K
House · MI · Aug 13, 2025
Buy$1K-$15K